Analysis of the activity of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in the field of clinical trials, registration of medicinal products and monitoring of adverse drug reactions in 2017-2021

Łukasz Dobrek

doi:10.56782/pps.120

Published : 2022-12-30

Vol. 20 No. 4 (2022)

Analysis of the activity of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in the field of clinical trials, registration of medicinal products and monitoring of adverse drug reactions in 2017-2021

Łukasz Dobrek

DOI: https://doi.org/10.56782/pps.120

Abstract

The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (ORMP) is the state registration authority that grants the marketing authorization for medicinal products on the pharmaceutical market in Poland. ORMP is also involved in approving and controlling clinical trials and in safety of pharmacotherapy (pharmacovigilance) by collecting and analysing reports of adverse drug reactions (ADR). The aim of the study was to review the activity of ORMP in the field of 3 basic competences of this authority: clinical trials, registration of medicinal products and pharmacovigilance in the last 5 years. The evaluation was carried out by the method of document analysis on the basis of data contained in annual bulletins of medicinal products for the years 2017-2021 published by ORMP. In 2017-2021, an increasing trend of clinical trials submitted to ORMP was observed, and they were mainly in phase II and III. Most of the medicinal products introduced to the Polish pharmaceutical market in 2017-2021 were drugs prescribed by a doctor, registered in a decentralized procedure, used in diseases of the nervous and cardiovascular systems and in the treatment of cancer. A relatively low activity of ORMP in monitoring the safety of pharmacotherapy was demonstrated, which was a consequence of low activity of medical staff in the spontaneous ADR reporting. The conducted analysis confirmed the key role of ORMP in surveillance of clinical trials and introducing new medicinal products to the pharmaceutical market in Poland but also indicated the need for increased activity in the area of pharmacovigilance.

Keywords:

drugs, medicinal products, registration, clinical trials, adverse drug reactions

Similar Articles

Joanna Stefańska, STAPHYLOCOCCAL RESISTANCE TO ANTIBACTERIAL AGENTS , Prospects in Pharmaceutical Sciences: Vol. 1 No. 3 (2003)
Monika Czerwińska, Marta Kuśnierek, Lycium barbarum fruits –phytochemistry and activity of goji berries – from tradition to clinical studies , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Piotr Wałejko, Stanisław Witkowski, POLYUNSATURATED FATTY ACIDS AND THEIR OXIDATION PRODUCTS , Prospects in Pharmaceutical Sciences: Vol. 14 No. 7 (2016)
Krzysztof Kubica, Aleksander Mazurek, VEMURAFENIB AS A SELECTIVE INHIBITOR OF THE SERINE/THREONINE-PROTEIN KINASE B-RAF, USED IN THE TREATMENT OF MELANOMA , Prospects in Pharmaceutical Sciences: Vol. 14 No. 8 (2016)
Elżbieta Hejchman, Dominik Lewandowski, SCHIFF BASE COPPER (II) COMPLEXES - NOVEL COMPOUNDS WITH ANTIMICROBIAL ACTIVITY , Prospects in Pharmaceutical Sciences: Vol. 15 No. 9 (2017)
Andrzej Tokarz, Małgorzata Jelińska, Agnieszka Ozga, ISOPROSTANES - NEW BIOMARKERS IN LIPID PEROXIDATION IN VIVO , Prospects in Pharmaceutical Sciences: Vol. 2 No. 2 (2004)
Aleksandra Grzybowska, Tomasz Lorenc, Wioletta Olejarz, Grażyna Nowicka, EXOSOMES AS CARRIERS OF INFORMATION BEETWEN TUMOR CELLS , Prospects in Pharmaceutical Sciences: Vol. 17 No. 2 (2019)
Adam Piasecki, Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison , Prospects in Pharmaceutical Sciences: Vol. 20 No. 1 (2022)
Martyna Chechłacz, Natalia Korytowska, COMPOUNDS THAT BIND TO PLASMA PROTEINS IN HUMANS. SIGNIFICANCE IN THERAPY AND METHODS FOR QUANTIFICATION OF A FREE FRACTION , Prospects in Pharmaceutical Sciences: Vol. 15 No. 6 (2017)
Zofia Suchocka, OBESITY - REASONS AND TREATMENT , Prospects in Pharmaceutical Sciences: Vol. 1 No. 1 (2003)

<< < 7 8 9 10 11 12 13 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Dobrek, Łukasz. (2022). Analysis of the activity of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in the field of clinical trials, registration of medicinal products and monitoring of adverse drug reactions in 2017-2021. Prospects in Pharmaceutical Sciences, 20(4), 1–8. https://doi.org/10.56782/pps.120

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.